{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:55:53Z","timestamp":1791377753487,"version":"4.3.2"},"reference-count":43,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust, the Institute of Cancer Research and Imperial College"},{"name":"Cancer Centre grant from Cancer Research U"},{"name":"Experimental Cancer Medicine Centre (ECMC) Initiative to The Institute of Cancer Research and Royal Marsden"},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013870","name":"Astex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013870","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,3,15]]},"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Data suggest that immunomodulation induced by DNA hypomethylating agents can sensitize tumors to immune checkpoint inhibitors. We conducted a phase 1 dose-escalation trial (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02998567\">NCT02998567<\/jats:ext-link>\n                      ) of guadecitabine and pembrolizumab in patients with advanced solid tumors. We hypothesized that guadecitabine will overcome pembrolizumab resistance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients received guadecitabine (45 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      or 30 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , administered subcutaneously on days 1\u20134), with pembrolizumab (200 mg administered intravenously starting from cycle 2 onwards) every 3 weeks. Primary endpoints were safety, tolerability and maximum tolerated dose; secondary and exploratory endpoints included objective response rate (ORR), changes in methylome, transcriptome, immune contextures in pre-treatment and on-treatment tumor biopsies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between January 2017 and January 2020, 34 patients were enrolled. The recommended phase II dose was guadecitabine 30 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , days 1\u20134, and pembrolizumab 200 mg on day 1 every 3 weeks. Two dose-limiting toxicities (neutropenia, febrile neutropenia) were reported at guadecitabine 45 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      with none reported at guadecitabine 30 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . The most common treatment-related adverse events (TRAEs) were neutropenia (58.8%), fatigue (17.6%), febrile neutropenia (11.8%) and nausea (11.8%). Common, grade 3+ TRAEs were neutropaenia (38.2%) and febrile neutropaenia (11.8%). There were no treatment-related deaths. Overall, 30 patients were evaluable for antitumor activity; ORR was 7% with 37% achieving disease control (progression-free survival) for \u226524 weeks. Of 12 evaluable patients with non-small cell lung cancer, 10 had been previously treated with immune checkpoint inhibitors with 5 (42%) having disease control \u226524 weeks (clinical benefit). Reduction in LINE\n                      <jats:italic>-<\/jats:italic>\n                      1 DNA methylation following treatment in blood (peripheral blood mononuclear cells) and tissue samples was demonstrated and methylation at transcriptional start site and 5\u2019 untranslated region gene regions showed enriched negative correlation with gene expression. Increases in intra-tumoural effector T-cells were seen in some responding patients. Patients having clinical benefit had high baseline inflammatory signature on RNAseq analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Guadecitabine in combination with pembrolizumab is tolerable with biological and anticancer activity. Reversal of previous resistance to immune checkpoint inhibitors is demonstrated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2022-004495","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T20:25:27Z","timestamp":1655583927000},"page":"e004495","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":58,"title":["Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02998567","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Dionysis","family":"Papadatos-Pastos","sequence":"first","affiliation":[{"name":"Clinical Research Facility, University College London Hospitals, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yuan","sequence":"additional","affiliation":[{"name":"Cancer Biomarkers Team, Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Pal","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateus","family":"Crespo","sequence":"additional","affiliation":[{"name":"Cancer Biomarkers Team, Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Cancer Biomarkers Team, Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Gurel","sequence":"additional","affiliation":[{"name":"Cancer Biomarkers Team, Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Prout","sequence":"additional","affiliation":[{"name":"Drug Development Unit - Investigator Initiated Trials Team, Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malaka","family":"Ameratunga","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Ch\u00e9nard-Poirier","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andra","family":"Curcean","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bertan","sequence":"additional","affiliation":[{"name":"Cancer Biomarkers Team, Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Baker","sequence":"additional","affiliation":[{"name":"Cancer Biomarkers Team, Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Miranda","sequence":"additional","affiliation":[{"name":"Cancer Biomarkers Team, Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahal","family":"Masrour","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Pereira","sequence":"additional","affiliation":[{"name":"Cancer Biomarkers Team, Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Figueiredo","sequence":"additional","affiliation":[{"name":"Cancer Biomarkers Team, Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Morilla","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Zachariou","sequence":"additional","affiliation":[{"name":"Drug Development Unit - Investigator Initiated Trials Team, Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Riisnaes","sequence":"additional","affiliation":[{"name":"Cancer Biomarkers Team, Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Parmar","sequence":"additional","affiliation":[{"name":"Drug Development Unit - Investigator Initiated Trials Team, Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Turner","sequence":"additional","affiliation":[{"name":"Drug Development Unit - Investigator Initiated Trials Team, Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5077-5379","authenticated-orcid":false,"given":"Suzanne","family":"Carreira","sequence":"additional","affiliation":[{"name":"Cancer Biomarkers Team, Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6715-2514","authenticated-orcid":false,"given":"Christina","family":"Yap","sequence":"additional","affiliation":[{"name":"Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tunariu","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udai","family":"Banerji","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanita","family":"Lopez","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[{"name":"Cancer Biomarkers Team, Institute of Cancer Research, Sutton, UK"},{"name":"Drug Development Unit, Royal Marsden Hospital\/Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9339-7101","authenticated-orcid":false,"given":"Anna","family":"Minchom","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,6,18]]},"reference":[{"key":"2025100314034189000_10.6.e004495.1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","article-title":"Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise","volume":"17","author":"Morel","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100314034189000_10.6.e004495.2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-380866-0.60002-2"},{"key":"2025100314034189000_10.6.e004495.3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2914"},{"key":"2025100314034189000_10.6.e004495.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2011.02.001"},{"key":"2025100314034189000_10.6.e004495.5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1442"},{"key":"2025100314034189000_10.6.e004495.6","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3020"},{"key":"2025100314034189000_10.6.e004495.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1365-7"},{"key":"2025100314034189000_10.6.e004495.8","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"2025100314034189000_10.6.e004495.9","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.273"},{"key":"2025100314034189000_10.6.e004495.10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3091"},{"key":"2025100314034189000_10.6.e004495.11","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.20540"},{"key":"2025100314034189000_10.6.e004495.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02630-w"},{"key":"2025100314034189000_10.6.e004495.13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062924"},{"key":"2025100314034189000_10.6.e004495.14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01443","article-title":"Immunomodulatory properties of DNA hypomethylating agents: selecting the optimal epigenetic partner for cancer immunotherapy","volume":"9","author":"Fazio","year":"2018","journal-title":"Front Pharmacol"},{"key":"2025100314034189000_10.6.e004495.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.011"},{"key":"2025100314034189000_10.6.e004495.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1201"},{"key":"2025100314034189000_10.6.e004495.17","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862"},{"key":"2025100314034189000_10.6.e004495.18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"key":"2025100314034189000_10.6.e004495.19","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.355"},{"key":"2025100314034189000_10.6.e004495.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03136"},{"key":"2025100314034189000_10.6.e004495.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01638"},{"key":"2025100314034189000_10.6.e004495.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149"},{"key":"2025100314034189000_10.6.e004495.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9"},{"key":"2025100314034189000_10.6.e004495.24","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30388-2"},{"key":"2025100314034189000_10.6.e004495.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.017"},{"key":"2025100314034189000_10.6.e004495.26","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"2025100314034189000_10.6.e004495.27","unstructured":"Diagnosis; NCIDoCTa . Common terminology criteria for adverse events (CTCAE), 2020. Available: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40 [Accessed 19 Oct 2020]."},{"key":"2025100314034189000_10.6.e004495.28","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"2025100314034189000_10.6.e004495.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"2025100314034189000_10.6.e004495.30","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2640"},{"key":"2025100314034189000_10.6.e004495.31","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1053\/j.seminoncol.2016.06.001","article-title":"Critical parameters in targeted drug development: the pharmacological audit TRAIL","volume":"43","author":"Banerji","year":"2016","journal-title":"Semin Oncol"},{"key":"2025100314034189000_10.6.e004495.32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00038-8"},{"key":"2025100314034189000_10.6.e004495.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0421"},{"key":"2025100314034189000_10.6.e004495.34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3055"},{"key":"2025100314034189000_10.6.e004495.35","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-1335","article-title":"Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial","volume":"25","author":"Di Giacomo","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025100314034189000_10.6.e004495.36","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1200\/JCO.2020.38.15_suppl.6025","article-title":"Phase II trial of guadecitabine priming and pembrolizumab in platinum resistant recurrent ovarian cancer","volume":"38","author":"Matei","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"2025100314034189000_10.6.e004495.37","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920975353","article-title":"Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review","volume":"12","author":"Yang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"2025100314034189000_10.6.e004495.38","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.497"},{"key":"2025100314034189000_10.6.e004495.39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.672328","article-title":"Epigenetic regulation of NK cell-mediated antitumor immunity","volume":"12","author":"Xia","year":"2021","journal-title":"Front Immunol"},{"key":"2025100314034189000_10.6.e004495.40","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1786888","article-title":"Pd-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates","volume":"9","author":"Pico de Coa\u00f1a","year":"2020","journal-title":"Oncoimmunology"},{"key":"2025100314034189000_10.6.e004495.41","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/exd.13263","article-title":"Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapy","volume":"26","author":"Tietze","year":"2017","journal-title":"Exp Dermatol"},{"key":"2025100314034189000_10.6.e004495.42","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jtcvs.2019.10.123","article-title":"Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors","volume":"159","author":"Jang","year":"2020","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025100314034189000_10.6.e004495.43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-57218-9","article-title":"Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer","volume":"10","author":"Hwang","year":"2020","journal-title":"Sci Rep"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-004495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T21:03:50Z","timestamp":1759525430000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-004495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,18]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/jitc-2022-004495"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-004495","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}